Arcus’s Casdatifan Differentiates, But Data Overshadowed By Gilead Opting Out

 
• By Mandy Jackson
  
Arcus put a bright spin on news that it regained full rights to casdatifan (Shutterstock)

More from Clinical Trials

More from Therapy Areas